RxDoctor Payments Data

Weilee Yeh, MD

Family Medicine · Hemet, CANPI 1104835065

Payments from drug & device makers

$1,232in general payments, 2019–2025

Across 66 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$367
  • Amgen$112
  • AstraZeneca$102
  • Neurocrine Biosciences, Inc.$66
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$62
  • Eisai Inc.$59
  • plus $464 from 16 others

What the payments were for

  • Food & beverage$1,232100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,232 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$402,867
Medicare patients
360
Services billed
3,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$96,622
EliquisApixaban200$91,508
JanuviaSitagliptin Phosphate82$61,762
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$51,289
XareltoRivaroxaban50$38,308
SantylCollagenase Clostridium Hist.15$21,699
JardianceEmpagliflozin53$21,671
TrulicityDulaglutide14$19,904
Repatha PushtronexEvolocumab31$18,723
MyrbetriqMirabegron18$18,055
XifaxanRifaximin14$17,883
EntrestoSacubitril/Valsartan31$12,034
LinzessLinaclotide23$11,172
Sevelamer Hcl12$11,161
GemtesaVibegron27$10,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$91,508200 claims
GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta$36$65,227124 claims
MerckJanuvia$21$61,76282 claims
Johnson & JohnsonXarelto, Invokana$13$44,03862 claims
Smith+NephewSantyl$12$21,69915 claims
Lilly USA, LLCTrulicity$30$19,90414 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$62$17,88314 claims
AbbVieLinzess$367$11,17223 claims
Sumitomo Pharma America, Inc.Gemtesa$24$10,77627 claims
AstraZenecaNexium$102$6,61711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →